![]() |
市場調查報告書
商品編碼
1503308
到 2030 年弱視市場預測:按類型、診斷、治療、應用和地區分類的全球分析Lazy Eye Market Forecasts to 2030 - Global Analysis By Type, Diagnosis, Treatment, Application and By Geography |
根據 Stratistics MRC 的數據,2024 年全球低視力市場規模為 32.6 億美元,預計到 2030 年將達到 49.2 億美元,預測期內複合年成長率為 7.1%。
當一個人戴著處方眼鏡或隱形眼鏡無法達到正常視力時,就會出現一種稱為弱視的發展性視力障礙。它通常始於兒童時期,當時眼睛和大腦仍在發育。弱視是一種大腦偏愛一隻眼睛而不是另一隻眼睛的疾病,導致受影響眼睛的視力下降。其他常見原因包括眼睛屈光不正的顯著差異、斜視(眼睛錯位)以及其他影響眼睛的疾病,例如白內障。
根據美國眼科學會的數據,弱視(俗稱忽視)是兒童視力喪失最常見的原因,在美國每 100 名兒童中約有 2 至 3 人受到影響。
弱視病例增加
由於多種因素,包括遺傳傾向、出生率上升以及螢幕使用和戶外活動減少等環境因素,弱視在世界各地變得越來越普遍。鑑於盛行率不斷增加,有效的診斷和管理方法至關重要。如果不及時治療,弱視可能會導致永久性視力障礙,因此早期發現至關重要。此外,隨著醫療保健提供者努力解決這一常見問題,對治療解決方案的需求不斷增加,推動市場成長。
最先進治療的價格過高
該市場成長的主要障礙之一是先進弱視治療的高成本,例如數位治療系統和專門的矯正鏡片。最終用戶必須為許多尖端解決方案支付高額成本,這是由於其研發、生產和行銷相關的高成本。沒有足夠醫療保險的家庭或生活在低收入地區的人可能會感到這種經濟負擔尤其沉重。此外,由於這個原因,這些治療方法的成本仍然是各個社會經濟群體採用和利用這些治療方法的主要障礙。
新興市場的成長
弱視治療市場在新興經濟體有著巨大的擴張潛力。拉丁美洲、亞洲和非洲國家都在經歷經濟成長,並正在發展醫療基礎設施。隨著對眼睛健康問題的了解和可支配收入的增加,對有效弱視治療的需求也增加。此外,對於有意進入這些市場的公司來說,很大程度上開拓的消費群可能是一個優勢。
患者依從性問題
成功的弱視治療最重要的方面之一是患者的依從性。許多治療方法,例如阿托品眼藥水和眼貼,必須長期持續使用才能有效。然而,患者的依從性很難維持,特別是當患者年輕並且可能對某些治療方法感到不舒服或受到恥辱時。此外,違規從可能導致治療結果不理想、降低治療效果並增加退出率。需要解決合規問題,以提高治療效果和市場永續性。
由於醫療保健服務中斷以及常規眼科檢查和治療的延誤,COVID-19 的爆發對弱視治療市場產生了重大影響。鎖上門和其他保持社交距離的策略減少了患者去看眼科醫師的次數,往往會延遲弱視的早期發現和治療。此外,由於疫情帶來的經濟負擔和經濟不安全感,一些家庭沒有優先考慮非緊急醫療保健,包括低視力治療。
斜視場預計在預測期間內最大
斜視弱視領域在斜視(弱視)市場佔有率最大。由於眼睛錯位(稱為斜視),斜視性弱視是最常見的弱視類型。為了防止雙眼視覺,大腦會優先考慮一隻眼睛而不是另一隻眼睛,從而導致未對準的眼睛的視覺發育不良。早期診斷和治療對於調整眼睛和改善視力至關重要。此外,這些手術通常涉及使用眼罩、矯正眼鏡或手術。
預計在預測期內,篩檢領域的複合年成長率最高。
斜視(弱視)市場的照片篩檢部分預計將以最高複合年成長率成長。照片篩檢涉及使用專用的相機和軟體為孩子的眼睛拍照。分析這些影像以查找弱視的危險因素,例如斜視和屈光不正。這種方法特別有益,因為它快速、非侵入性且易於使用,即使對於不配合傳統眼科檢查的幼兒也是如此。此外,由於多種因素,該市場正在迅速擴大,包括兒科篩檢的普及、照片篩檢技術的進步以及對早期檢測價值的日益了解。
北美,尤其是美國,由於先進的醫療保健系統、較高的認知度和易於獲得的治療方案而在弱視市場中佔據主導地位。由於失智症在美國非常普遍,因此有一個健康的市場,得到強大的製藥公司、受人尊敬的研究設施以及治療視力喪失的積極方法的支持。此外,該國在北美盲眼市場的巨大市場佔有率歸因於其對醫療保健創新和治療方式的廣泛可用性的關注。
中國、日本和印度等亞太地區的複合年成長率最高。醫療保健成本上升、公眾對眼科疾病的認知不斷提高以及獲得醫療保健的便利性(尤其是在農村地區)等因素正在推動這一成長。此外,中國和印度等國家由於人口眾多、弱視病例不斷增加以及注重發展醫療基礎設施,預計將顯著成長。
According to Stratistics MRC, the Global Lazy Eye Market is accounted for $3.26 billion in 2024 and is expected to reach $4.92 billion by 2030 growing at a CAGR of 7.1% during the forecast period. A vision development disorder known as lazy eye, or amblyopia, occurs when one eye is unable to achieve normal visual acuity, even with prescription eyeglasses or contact lenses. It usually begins in childhood, when the eyes and brain are still growing. Amblyopia is a condition in which the brain prefers one eye over the other, impairing vision in the affected eye. Moreover, common causes include significant differences in the prescription (refractive error) between the two eyes, strabismus (misalignment of the eyes), or other conditions affecting the eyes, such as cataracts.
According to the American Academy of Ophthalmology, amblyopia, commonly known as lazy eye, is the most common cause of visual impairment in children, affecting approximately 2 to 3 out of every 100 children in the United States.
Growing number of amblyopia cases
Due to a number of factors, including genetic predispositions, rising birth rates, and environmental factors like screen time and fewer outdoor activities, amblyopia is becoming more commonplace worldwide. An efficient diagnosis and management approach is imperative in light of this increasing prevalence. It is imperative to detect amblyopia early on because, if left untreated, it can cause permanent visual impairments. Moreover, as healthcare providers strive to address this prevalent condition, the demand for treatment solutions is growing, driving market growth.
Exorbitant price of cutting-edge therapies
One major obstacle to the growth of this market is the high cost of advanced amblyopia treatments, such as digital therapy systems and specialty corrective lenses. The high costs that end users must pay for many of these cutting-edge solutions stem from the significant costs associated with their R&D, production, and marketing. Families without sufficient health insurance or those residing in low-income areas may find this financial burden especially difficult. Additionally, because of this, the cost of these treatments continues to be a major barrier to their adoption and accessibility by a variety of socioeconomic groups.
Growth in emerging markets
There is a big chance for the market for amblyopia treatments to expand in emerging economies. Latin American, Asian, and African nations are all seeing increases in their economies, as well as improvements to their infrastructure for healthcare. The demand for efficient amblyopia treatments is raising as knowledge of eye health issues and disposable incomes both rise. Furthermore, a largely unexplored consumer base can be advantageous to businesses that deliberately enter these markets.
Problems with Patient Compliance
One of the most important aspects of amblyopia treatment success is patient compliance. For many treatment modalities, like atropine drops and eye patches, to be effective, they must be used consistently over an extended period of time. But it can be difficult to keep patients compliant, particularly when they are young and may find certain treatments upsetting or stigmatizing. Moreover, non-compliance may result in less than ideal treatment results, which may lower the treatments' perceived efficacy and possibly increase the dropout rate. Improving the effectiveness of treatment and the sustainability of the market require addressing compliance issues.
Due to disruptions in healthcare services and delays in routine eye examinations and treatments, the COVID-19 pandemic had a significant effect on the amblyopia treatment market. Lockdowns and other social distancing tactics decreased patient visits to ophthalmologists, which in many cases delayed the early detection and treatment of amblyopia. Additionally, some families deprioritized non-emergency healthcare, including treatment for amblyopia, due to financial strain and economic uncertainty brought on by the pandemic.
The Strabismic segment is expected to be the largest during the forecast period
The Strabismic Amblyopia segment has the largest market share in lazy eye (amblyopia). As a result of an eye misalignment known as strabismus, strabismic amblyopia is the most prevalent type of amblyopia. Poor visual development in the misaligned eye results from the brain favoring one eye over the other to prevent double vision. In order to align the eyes and improve vision, early diagnosis and treatment are essential. Furthermore, these procedures frequently involve the use of eye patches, corrective glasses, or surgery.
The Photo screening segment is expected to have the highest CAGR during the forecast period
The photo screening segment of the lazy eye (amblyopia) market is anticipated to grow at the highest CAGR. Photo screening is taking pictures of a child's eyes with specialized cameras and software. These images are then analyzed to find amblyopia risk factors like strabismus or refractive errors. Because it is quick, non-invasive, and simple to use on young children who might not cooperate for traditional eye exams, this method is especially beneficial. Moreover, this market is expanding quickly due to a number of factors, including increased adoption of pediatric screenings, photo screening technology advancements, and a growing understanding of the value of early detection.
Due to its sophisticated healthcare system, high awareness, and easy access to treatment options, North America-and especially the United States-dominate the market for lazy eyes. Because lazy eye cases are so common in the US, there is a healthy market there that is backed by strong pharmaceutical companies, esteemed research facilities, and a proactive approach to treating vision disorders. Additionally, the nation's notable market share in the North American lazy eye market can be attributed to its focus on healthcare innovation and the extensive accessibility of treatment modalities.
The lazy eye market has the highest CAGR in the Asia-Pacific region, which includes nations like China, Japan, and India. Factors like rising healthcare costs, increased public awareness of eye conditions, and easier access to healthcare, especially in rural areas, are driving this growth. Furthermore, with their sizable populations, nations like China and India present substantial growth prospects because of the increased incidence of lazy eye cases and the increased attention being paid to the development of healthcare infrastructure.
Key players in the market
Some of the key players in Lazy Eye market include Johnson And Johnson Services, Inc, Golden Vision, Krafty Eye Patches, Adwia Pharmaceuticals, NovaSight, 3M, Pfizer Inc, TCI Chemicals Pvt. Ltd, Rebion, Bausch & Lomb Incorporated, Opthopatch, Vivid Vision, Inc, Hilco Vision, Walgreens and Fresnel Prism & Lens.
In May 2024, Johnson & Johnson has entered into a definitive agreement to acquire Proteologix Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with potential for an additional milestone payment.
In January 2024, 3M Health Care announced that its Medical Solutions Division received a $34.2 million award from the U.S. Army Medical Research Acquisition Activity. The award enables 3M to develop a range of new solutions for infection prevention, wound management and wound healing.
In September 2023, Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies Inc. announced it has completed its acquisition of XIIDRA(R) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.